Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease
Authors
Keywords
Type 2 diabetes, NAFLD, Intestine-liver cross-talk
Journal
METABOLISM-CLINICAL AND EXPERIMENTAL
Volume 123, Issue -, Pages 154844
Publisher
Elsevier BV
Online
2021-08-01
DOI
10.1016/j.metabol.2021.154844
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of the gut microbiota in type 2 diabetes and related diseases
- (2021) Ge Yang et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity
- (2021) Maxime Nachit et al. JOURNAL OF HEPATOLOGY
- Akkermansia muciniphila Prevents Fatty Liver, Decreases Serum Triglycerides, and Maintains Gut Homeostasis
- (2020) Sejeong Kim et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease
- (2020) Eleonora Scorletti et al. GASTROENTEROLOGY
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
- (2020) Donatella Chianelli et al. JOURNAL OF MEDICINAL CHEMISTRY
- The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids
- (2020) Sarah Ducastel et al. Scientific Reports
- Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability
- (2020) Laura Craven et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis
- (2020) Keith M. Wirth et al. ANNALS OF SURGERY
- Nonalcoholic Steatohepatitis
- (2020) Adam C. Sheka et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
- (2020) Judith Aron-Wisnewsky et al. Nature Reviews Gastroenterology & Hepatology
- The Impact of Bariatric Surgery on Hepatic Function and Predictors of Liver Steatosis and Fibrosis
- (2020) Marta Borges-Canha et al. OBESITY SURGERY
- The Paneth Cell: The Curator and Defender of the Immature Small Intestine
- (2020) Shiloh R. Lueschow et al. Frontiers in Immunology
- Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
- (2020) Guillaume Lassailly et al. GASTROENTEROLOGY
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
- (2020) Stephen A Harrison et al. Lancet Gastroenterology & Hepatology
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
- (2020) Alessandro Mantovani et al. GUT
- Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial
- (2020) Vahideh Behrouz et al. JOURNAL OF FOOD SCIENCE
- Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis
- (2020) Toon J. I. De Munck et al. LIVER INTERNATIONAL
- Gut microbiota in human metabolic health and disease
- (2020) Yong Fan et al. NATURE REVIEWS MICROBIOLOGY
- Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes
- (2020) Torsten P. M. Scheithauer et al. Frontiers in Immunology
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
- (2020) Wen Guo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease
- (2020) Yun‐Cheng Hsieh et al. LIVER INTERNATIONAL
- Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice
- (2020) Ting Bao et al. Frontiers in Pharmacology
- Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice
- (2019) Patricia D. Finn et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Metabolic (Bariatric and Nonbariatric) Surgery for Type 2 Diabetes: A Personal Perspective Review
- (2019) Henry Buchwald et al. DIABETES CARE
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes
- (2019) Oscar Chávez-Talavera et al. CURRENT OPINION IN LIPIDOLOGY
- Leaky gut: mechanisms, measurement and clinical implications in humans
- (2019) Michael Camilleri GUT
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Non‐Alcoholic Fatty Liver Disease, Liver Fibrosis Score and Cognitive Function in Middle‐Aged Adults: The Framingham Study
- (2019) Galit Weinstein et al. LIVER INTERNATIONAL
- Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
- (2019) Sang Bong Ahn et al. Scientific Reports
- Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
- (2019) Juliette Mouries et al. JOURNAL OF HEPATOLOGY
- CD8+T CELLS REGULATE LIVER INJURY IN OBESITY-RELATED NONALCOHOLIC FATTY LIVER DISEASE
- (2019) Denitra A Breuer et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes
- (2019) A. Mantovani et al. DIABETES & METABOLISM
- Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes
- (2019) D.H. Seo et al. DIABETES & METABOLISM
- Gut-associated IgA+ immune cells regulate obesity-related insulin resistance
- (2019) Helen Luck et al. Nature Communications
- Increased liver localization of lipopolysaccharides in human and experimental non‐alcoholic fatty liver disease
- (2019) Guido Carpino et al. HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism
- (2018) Preeti Pathak et al. HEPATOLOGY
- Lactobacillus acidophilus NS1 attenuates diet-induced obesity and fatty liver
- (2018) Sung-Soo Park et al. JOURNAL OF ENDOCRINOLOGY
- INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function
- (2018) Paolo Comeglio et al. JOURNAL OF ENDOCRINOLOGY
- Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
- (2018) Amedeo Lonardo et al. JOURNAL OF HEPATOLOGY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement
- (2018) Frédéric Brioude et al. Nature Reviews Endocrinology
- Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review
- (2018) Katia P. Souto et al. Surgery for Obesity and Related Diseases
- Intestinal Intraepithelial Lymphocytes: Sentinels of the Mucosal Barrier
- (2018) Danyvid Olivares-Villagómez et al. TRENDS IN IMMUNOLOGY
- INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- (2018) Jonathan D Roth et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study
- (2018) Galit Weinstein et al. JAMA Neurology
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
- (2018) Emma Ahlqvist et al. Lancet Diabetes & Endocrinology
- Innate Lymphoid Cells: 10 Years On
- (2018) Eric Vivier et al. CELL
- Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis
- (2018) Sebastiaan De Schepper et al. CELL
- Rifaximin in nonalcoholic fatty liver disease
- (2018) Ahmed Abdel-Razik et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease
- (2018) Huikuan Chu et al. GUT
- Apoptosis and necroptosis in the liver: a matter of life and death
- (2018) Robert F. Schwabe et al. Nature Reviews Gastroenterology & Hepatology
- Mechanisms of Insulin Action and Insulin Resistance
- (2018) Max C. Petersen et al. PHYSIOLOGICAL REVIEWS
- Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD
- (2018) Cyrielle Caussy et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1
- (2018) Ara Koh et al. CELL
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
- (2017) Oscar Chávez-Talavera et al. GASTROENTEROLOGY
- Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration
- (2017) Gloria Alvarez-Sola et al. GUT
- Human Secretory IgM Emerges from Plasma Cells Clonally Related to Gut Memory B Cells and Targets Highly Diverse Commensals
- (2017) Giuliana Magri et al. IMMUNITY
- Immunologic impact of the intestine in metabolic disease
- (2017) Daniel A. Winer et al. JOURNAL OF CLINICAL INVESTIGATION
- Treatment of NAFLD with diet, physical activity and exercise
- (2017) Manuel Romero-Gómez et al. JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study
- (2017) Karlijn J. Nass et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics
- (2017) Glenn R. Gibson et al. Nature Reviews Gastroenterology & Hepatology
- Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier
- (2017) Da Zhou et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis
- (2017) Chien-Chao Chiu et al. Nutrients
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila
- (2017) Patrice D. Cani et al. Frontiers in Microbiology
- Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
- (2016) Joel T. Haas et al. Annual Review of Physiology
- From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
- (2016) Ara Koh et al. CELL
- Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
- (2016) Annika Wahlström et al. Cell Metabolism
- Colonic Pro-inflammatory Macrophages Cause Insulin Resistance in an Intestinal Ccl2/Ccr2-Dependent Manner
- (2016) Yoshinaga Kawano et al. Cell Metabolism
- Obeticholic Acid: First Global Approval
- (2016) A. Markham et al. DRUGS
- Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol
- (2016) Khalidur Rahman et al. GASTROENTEROLOGY
- Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury
- (2016) Elena Arriazu et al. GUT
- Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis
- (2016) Benjamin Lelouvier et al. HEPATOLOGY
- What Makes MAITs Wait?
- (2016) Mark A. Exley IMMUNITY
- Peyer's patches: organizing B-cell responses at the intestinal frontier
- (2016) Andrea Reboldi et al. IMMUNOLOGICAL REVIEWS
- Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes
- (2016) David P. Sonne et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
- (2016) Jeffrey Cui et al. JOURNAL OF HEPATOLOGY
- Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease
- (2016) Panu K. Luukkonen et al. JOURNAL OF HEPATOLOGY
- Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice
- (2016) Kamaljit K. Chaudhry et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Diet–microbiota interactions as moderators of human metabolism
- (2016) Justin L. Sonnenburg et al. NATURE
- Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
- (2016) Nathan D Mathewson et al. NATURE IMMUNOLOGY
- NAFLD and diabetes mellitus
- (2016) Herbert Tilg et al. Nature Reviews Gastroenterology & Hepatology
- Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet
- (2016) Douglas Mahana et al. Genome Medicine
- Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling
- (2015) Milena Monteiro-Sepulveda et al. Cell Metabolism
- Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
- (2015) Guillaume Lassailly et al. GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
- (2015) Mohamed-Sami Trabelsi et al. Nature Communications
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
- (2015) Changtao Jiang et al. Nature Communications
- Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis
- (2014) A. Alisi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study
- (2014) Tannaz Eslamparast et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Intestinal Lipid Handling
- (2014) Alain Veilleux et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system
- (2014) Thaher Pelaseyed et al. IMMUNOLOGICAL REVIEWS
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
- (2014) Changtao Jiang et al. JOURNAL OF CLINICAL INVESTIGATION
- The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
- (2014) Rachel J. Perry et al. NATURE
- The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
- (2014) Colin Hill et al. Nature Reviews Gastroenterology & Hepatology
- Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
- (2014) Gerald I. Shulman NEW ENGLAND JOURNAL OF MEDICINE
- Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease
- (2014) Lucia Pacifico WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
- (2013) Vincent Wai-Sun Wong et al. JOURNAL OF HEPATOLOGY
- Richness of human gut microbiome correlates with metabolic markers
- (2013) Emmanuelle Le Chatelier et al. NATURE
- Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
- (2013) Yukihiro Furusawa et al. NATURE
- Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
- (2013) Nicholas Arpaia et al. NATURE
- Gut metagenome in European women with normal, impaired and diabetic glucose control
- (2013) Fredrik H. Karlsson et al. NATURE
- Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
- (2013) Els van Nood et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
- (2013) Fei Li et al. Nature Communications
- Absence of Acute Inhibitory Effect of Insulin on Chylomicron Production in Type 2 Diabetes
- (2012) Juan-Patricio Nogueira et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome
- (2012) Anne Vrieze et al. GASTROENTEROLOGY
- Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH
- (2012) Lixin Zhu et al. HEPATOLOGY
- A metagenome-wide association study of gut microbiota in type 2 diabetes
- (2012) Junjie Qin et al. NATURE
- Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
- (2011) J. Prawitt et al. DIABETES
- The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice
- (2011) Yan-Dong Wang et al. HEPATOLOGY
- Intestinal Tolerance Requires Gut Homing and Expansion of FoxP3+ Regulatory T Cells in the Lamina Propria
- (2011) Usriansyah Hadis et al. IMMUNITY
- Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid–induced ceramide biosynthesis in mice
- (2011) William L. Holland et al. JOURNAL OF CLINICAL INVESTIGATION
- Ceramides as modulators of cellular and whole-body metabolism
- (2011) Benjamin T. Bikman et al. JOURNAL OF CLINICAL INVESTIGATION
- PKCδ regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans
- (2011) Olivier Bezy et al. JOURNAL OF CLINICAL INVESTIGATION
- Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans
- (2011) Jussi Pihlajamäki et al. JOURNAL OF HEPATOLOGY
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
- (2011) Zeneng Wang et al. NATURE
- Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism
- (2010) Gemma Brufau et al. HEPATOLOGY
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
- (2009) Luca Miele et al. HEPATOLOGY
- Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice
- (2008) P. D. Cani et al. DIABETES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More